Rznomics RZ-001 Shows 61.5% Response Rate in Hepatocellular Carcinoma Trial at AACR 2026

Key Takeaways

• RZ-001 achieved 61.5% objective response rate using mRECIST criteria with 23% complete response rate in hepatocellular carcinoma patients
• No Grade 3 or higher adverse events related to RZ-001 were observed, demonstrating favorable safety profile for the RNA editing therapy
• Interim results support continued development of this novel anticancer approach, with full study data expected to guide next phase of clinical development

---

Rznomics announced promising interim clinical results for RZ-001, its investigational RNA editing-based anticancer therapy, in patients with hepatocellular carcinoma (HCC) during an oral presentation at the American Association for Cancer Research (AACR) 2026 conference on April 20, 2026.

Strong Efficacy Signals Across Multiple Measures

The interim data revealed encouraging efficacy across different response criteria. Using RECIST criteria, RZ-001 demonstrated a confirmed objective response rate (ORR) of 38.5% and an unconfirmed ORR of 46.2%. More notably, when evaluated using mRECIST criteria—specifically designed for liver cancer assessment—the therapy achieved a 61.5% ORR with an impressive 23% complete response rate.

IntelligenceRegulatory Impact▾

NMPA, PMDA, and TGA are the agencies to watch. Regulatory relevance reads medium for pharmaceutical intelligence. Teams should track submission types, designations, and guidance shifts that could move approval timelines.

Favorable Safety Profile Supports Continued Development

The safety data proved equally compelling, with no Grade 3 or higher adverse events attributed to RZ-001 observed during the interim analysis period. This safety profile is particularly significant for hepatocellular carcinoma patients, who often have underlying liver dysfunction that can complicate treatment tolerability.

IntelligenceCompetitive Intelligence▾

Competitive pressure is low. Watch which sponsors move first. Benchmark pipeline positioning, differentiation, and partnership scouting against the signals in this story.

RNA Editing Represents Novel Therapeutic Approach

RZ-001 represents an innovative approach to cancer treatment through RNA editing technology, which allows for precise modification of RNA sequences to potentially correct disease-causing mutations or enhance therapeutic responses. This mechanism of action differentiates it from traditional chemotherapy, targeted therapy, and immunotherapy approaches currently used in HCC treatment.

IntelligenceMarket Signals▾

Commercial pull is medium and investment relevance low. Expect implications for pharmaceutical intelligence pricing, access, and launch sequencing.

Market Impact and Clinical Context

Hepatocellular carcinoma remains a significant unmet medical need, representing the most common form of primary liver cancer globally. Current treatment options for advanced HCC include sorafenib, lenvatinib, and various immunotherapy combinations, but response rates and overall survival remain limited.

The Seoul-based biotechnology company’s results suggest RZ-001 could potentially offer a new treatment paradigm for HCC patients. The combination of strong efficacy signals and favorable safety profile positions the therapy as a promising candidate for further clinical development.

IntelligenceStrategic Takeaways▾

RZ-001 achieved 61.5% objective response rate using mRECIST criteria with 23% complete response rate in hepatocellular carcinoma patients No Grade 3 or higher adverse events related to RZ-001 were observed, demonstrating favorable safety profile for the RNA editing therapy Interim results support continued development of this novel anticancer approach, with full study data expected to guide next phase of clinical development

Next Steps in Development

While these interim results are encouraging, Rznomics will need to complete the full study to establish definitive efficacy and safety profiles. The company has not yet announced timeline for study completion or plans for potential registration-enabling trials.

---

Frequently Asked Questions

What does this mean for hepatocellular carcinoma patients?

The results suggest RZ-001 could potentially offer a new treatment option with strong response rates (61.5%) and favorable safety compared to existing therapies, though the drug is still in clinical trials and not yet available to patients.

When will RZ-001 be available for patients?

RZ-001 is currently in clinical trials with no announced timeline for completion. If successful, the therapy would still need to complete additional studies and regulatory approval before becoming commercially available, likely several years away.

How does RZ-001 compare to existing hepatocellular carcinoma treatments?

The 61.5% response rate appears promising compared to current HCC therapies like sorafenib and lenvatinib, which typically show response rates of 10-20%, though direct comparisons require head-to-head studies.

Related coverage

• Orion Pharma's ODM-212 Shows Favorable Safety in Phase 1/2 TEADES Trial for Advanced Solid Tumours
• ASCO 2026: Asian Oncology Innovation Takes Center Stage, Driving Global Clinical Trial Advancements
• Clinical Trials Outsourcing Market Size: 2026-2034 Growth Outlook